Indo-European Consortium for Next Generation Influenza Vaccine Innovation

Informacje na temat projektu

INCENTIVE

Identyfikator umowy o grant: 874866

DOI

10.3030/874866

Projekt został zamknięty

Data podpisania przez KE 13 Grudnia 2019

Data rozpoczęcia 1 Sierpnia 2020

Data zakończenia 31 Stycznia 2026

Finansowanie w ramach

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Koszt całkowity

€ 19 965 992,50

Wkład UE

€ 9 974 293,75

Koordynowany przez

HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH
Germany

CORDIS oferuje możliwość skorzystania z odnośników do publicznie dostępnych publikacji i rezultatów projektów realizowanych w ramach programów ramowych HORYZONT.

Odnośniki do rezultatów i publikacji związanych z poszczególnymi projektami 7PR, a także odnośniki do niektórych konkretnych kategorii wyników, takich jak zbiory danych i oprogramowanie, są dynamicznie pobierane z systemu OpenAIRE .

Rezultaty

Documents, reports (4)

INCENTIVE-QIV-1,2,3 (EU) and QIV-1 (India): Study results posted in the study registry

Safety and preliminary immunogenicity results posted on the study registry. Timelines if/when final posting of results is scheduled after end of funding period will be included.

INCENTIVE-QIV: Registration of the clinical trial in the trial registry

Study registered at a WHO or ICMJapproved registry

Development and annual update of INCENTIVE dissemination and exploitation plan delivered

Plan and annual update on dissemination activities and IP exploitation.

A blueprint for rolling out stratified influenza vaccination programs, in order to optimize / maximize efficiency and effectiveness taking into account acceptability, affordability and accessibility issues

Development of blueprint for the rollout of stratified influenza vaccination program.

Websites, patent fillings, videos etc. (1)

Project presentation prepared, website launched and communication plan developed

Setting up consortium website public and secured intranet Communication plan regulating the consortium communication

Publikacje

Peer reviewed articles (14)

Human Organotypic Airway and Lung Organoid Cells of Bronchiolar and Alveolar Differentiation Are Permissive to Infection by Influenza and SARS-CoV-2 Respiratory Virus

Autorzy: Camilla Tvedt Ekanger, Fan Zhou, Dana Bohan, Maria Lie Lotsberg, Maria Ramnefjell, Laurence Hoareau, Gro Vatne Røsland, Ning Lu, Marianne Aanerud, Fabian Gärtner, Pirjo Riitta Salminen, Mariann Bent
Opublikowane w: Frontiers in Cellular and Infection Microbiology, Numer 12, 2022, Strona(/y) 841447, ISSN 2235-2988
Wydawca: Frontiers Media S. A.
DOI: 10.3389/fcimb.2022.841447

Seasonal influenza vaccination expands hemagglutinin-specific antibody breadth to older and future A/H3N2 viruses

Autorzy: Nina Urke Ertesvåg, Rebecca Jane Cox, Sarah Larteley Lartey, Kristin G-I Mohn, Karl Albert Brokstad, Mai-Chi Trieu
Opublikowane w: npj Vaccines, Numer 7, 2022, Strona(/y) 490, ISSN 2059-0105
Wydawca: Springer Science and Business Media LLC
DOI: 10.1038/s41541-022-00490-0

Intranasal administration of octavalent next-generation influenza vaccine elicits protective immune responses against seasonal and pre-pandemic viruses

Autorzy: Naoko Uno, Thomas Ebensen, Carlos A. Guzman, Ted M. Ross
Opublikowane w: Journal of Virology, Numer 98, 2024, ISSN 0022-538X
Wydawca: American Society for Microbiology
DOI: 10.1128/jvi.00354-24

Effects of repeated influenza vaccination and infection on durable seroprotection in healthcare workers

Autorzy: Mai-Chi Trieu, Amit Bansal, Marianne Sævik, Sonja Ljostveit, Åsne Jul-Larsen, Rebecca Jane Cox
Opublikowane w: npj Vaccines, Numer 10, 2025, Strona(/y) 1259, ISSN 2059-0105
Wydawca: Springer Science and Business Media LLC
DOI: 10.1038/s41541-025-01259-x

Influenza hemagglutinin and neuraminidase multivalent vaccine elicits broader protective immune responses compared to vaccine formulations composed of hemagglutinin or neuraminidase

Autorzy: Naoko Uno, Ted M. Ross
Opublikowane w: Human Vaccines & Immunotherapeutics, Numer 21, 2026, Strona(/y) 259961, ISSN 2164-5515
Wydawca: Landes Bioscience
DOI: 10.1080/21645515.2025.2599611

Repeated Influenza Vaccination Boosts and Maintains H1N1pdm09 Neuraminidase Antibody Titers

Autorzy: Lena Hansen, Fan Zhou, Håkon Amdam, Mai-Chi Trieu, Rebecca Jane Cox
Opublikowane w: Frontiers in Immunology, Numer 12, 2021, Strona(/y) 748264, ISSN 1664-3224
Wydawca: Frontiers Media SA
DOI: 10.3389/fimmu.2021.748264

Impact of Pre-Existing Immunity and Age on Antibody Responses to Live Attenuated Influenza Vaccine

Autorzy: Lukas Hoen, Sarah Lartey, Fan Zhou, Rishi D. Pathirana, Florian Krammer, Kristin G -I Mohn, Rebecca J. Cox, Karl A. Brokstad
Opublikowane w: Vaccines, Numer 12, 2025, Strona(/y) 864, ISSN 2076-393X
Wydawca: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/vaccines12080864

Matrix M Adjuvanted H5N1 Vaccine Elicits Broadly Neutralizing Antibodies and Neuraminidase Inhibiting Antibodies in Humans That Correlate With In Vivo Protection

Autorzy: Fan Zhou, Lena Hansen, Gabriel Pedersen, Gunnveig Grødeland, Rebecca Cox
Opublikowane w: Frontiers in Immunology, Numer 12, 2021, Strona(/y) 747774, ISSN 1664-3224
Wydawca: Frontiers Media SA
DOI: 10.3389/fimmu.2021.747774

Next Generation Influenza Vaccines: Looking into theCrystal Ball

Autorzy: Carlos Alberto Guzmán
Opublikowane w: Vaccines, 2020, ISSN 2076-393X
Wydawca: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/vaccines8030464

DNA vaccines targeting hemagglutinin from 18 subtypes of influenza A virus to antigen-presenting cells confer broad protection

Autorzy: Ane Marie Anderson, Elias Tjärnhage, Daniëla Maria Hinke, Ranveig Braathen, Gunnveig Grodeland, Bjarne Bogen
Opublikowane w: Molecular Therapy Nucleic Acids, Numer 37, 2026, Strona(/y) 102814, ISSN 2162-2531
Wydawca: Nature Publishing Group
DOI: 10.1016/j.omtn.2025.102814

Point-of-Care Influenza Testing Impacts Clinical Decision, Patient Flow, and Length of Stay in Hospitalized Adults

Autorzy: Elisabeth B Fjelltveit, Rebecca J Cox, Jørgen Østensjø, Bjørn Blomberg, Marit H Ebbesen, Nina Langeland, Kristin G I Mohn
Opublikowane w: The Journal of Infectious Diseases, Numer 226, 2022, Strona(/y) 97-108, ISSN 0022-1899
Wydawca: University of Chicago Press
DOI: 10.1093/infdis/jiaa690

Safety, Immunogenicity, Efficacy and Effectiveness of Inactivated Influenza Vaccines in Healthy Pregnant Women and Children Under 5 Years: An Evidence-Based Clinical Review

Autorzy: Amit Bansal, Mai-Chi Trieu, Kristin G. I. Mohn, Rebecca Jane Cox
Opublikowane w: Frontiers in Immunology, Numer 12, 2021, Strona(/y) 744774, ISSN 1664-3224
Wydawca: Frontiers Media SA
DOI: 10.3389/fimmu.2021.744774

Multivalent next generation influenza virus vaccines protect against seasonal and pre-pandemic viruses

Autorzy: Naoko Uno, Ted M. Ross
Opublikowane w: Scientific Reports, Numer 14, 2024, ISSN 2045-2322
Wydawca: Nature Publishing Group
DOI: 10.1038/s41598-023-51024-0

Prospects and Challenges in the Development of Universal Influenza Vaccines

Autorzy: Anders Madsen, Rebecca Jane Cox
Opublikowane w: Vaccines, Numer 8, 2025, Strona(/y) 361, ISSN 2076-393X
Wydawca: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/vaccines8030361